Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics Receives Notification of PDUFA Extension for ZULRESSO™ (brexanolone) Injection
PDUFA goal date extended to March 19, 2019 to finalize REMS No additional clinical data or information requested by the FDA CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2018-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat
View HTML
Toggle Summary Sage Therapeutics to Present at Stifel 2018 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Stifel 2018 Healthcare
View HTML
Toggle Summary Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
FDA Advisory Committee Meeting outcome supports approval of ZULRESSO™ (brexanolone) injection as the first medicine specifically indicated for the treatment of postpartum depression (PPD) Continuing to execute commercial strategy for ZULRESSO in PPD ahead of PDUFA target date of December 19, 2018
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on November 1, 2018 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO™ (brexanolone) Injection for Treatment of Postpartum Depression
If approved, ZULRESSO would be the first medicine specifically indicated for the treatment of postpartum depression (PPD) CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering
View HTML
Toggle Summary Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss ZULRESSO™ (brexanolone) Injection for the Treatment of Postpartum Depression
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that NASDAQ has halted trading of the company’s common stock.
View HTML
Toggle Summary Sage Therapeutics to Report Third Quarter 2018 Financial Results on Tuesday, November 6, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 23, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 3, 2018-- Sage Therapeutics  (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on October 1, 2018 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Morgan Stanley 16th Annual
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on September 4, 2018 , the Compensation Committee of
View HTML